Candel Therapeutics
CADL
52 hedge funds and large institutions have $46.4M invested in Candel Therapeutics in 2024 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 8 closing their positions.
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
25% more capital invested
Capital invested by funds: $37M → $46.4M (+$9.42M)
16% more funds holding
Funds holding: 45 → 52 (+7)
0.83% more ownership
Funds ownership: 20.03% → 20.86% (+0.83%)
16% less call options, than puts
Call options by funds: $803K | Put options by funds: $957K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HFF
Halter Ferguson Financial
Carmel,
Indiana
|
+$1.89M |
| 2 |
BlackRock
New York
|
+$1.88M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$841K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$793K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$716K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.96M |
| 2 |
MML Investors Services
Springfield,
Massachusetts
|
-$317K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$202K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$162K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$160K |
CADL Hedge Fund Activity: Q3 2024 in Review
52 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q3 2024, worth a combined $46.4M — up 25% from $37M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CADL positions and 8 closed out — a net gain of 7 holders — while 17 added to existing stakes and 10 trimmed.
The largest buyer was Halter Ferguson Financial, opening a new position worth an estimated $1.89M. The largest seller was Nuveen, cutting an estimated $1.96M.
- 52 institutional investors held Candel Therapeutics (CADL) as of Q3 2024, up from 45 in Q2 2024.
- Funds reported $46.4M of Candel Therapeutics stock for Q3 2024, up 25% quarter-over-quarter.
- 15 funds opened new Candel Therapeutics positions in Q3 2024 and 8 closed out, a net change of +7 holders.
- The largest Candel Therapeutics buyer in Q3 2024 was Halter Ferguson Financial, an estimated $1.89M added.
- The largest Candel Therapeutics seller in Q3 2024 was Nuveen, an estimated $1.96M sold.
Based on aggregated 13F filings for Q3 2024.